Urogen's Novel Formula For Urothelial Cancer Presents Unique Commercial Challenges
The company expects to launch a proprietary gel formulation of chemo drug mitomycin for urothelial cancer in the first half of 2020.
You may also be interested in...
Jelmyto relies on a proprietary sustained-release drug delivery technology that UroGen plans to use for future drugs. The company is moving ahead with a launch in June, relying on virtual technology.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
UroGen's reverse thermal gel formulation of mitomycin produced a high rate of complete responses in patients with urothelial cancer; developing a commercialization strategy for the product will benefit from the experience of the company's new CEO.